A Phase 2/3 interventional study of Inebilizumab and Placebo in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders, sponsored by MedImmune LLC. Completed at 98 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is one of 2 that started in 2015, is one of 3 in phase 2/3, and was the 3rd registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Alexion Pharmaceuticals, Inc. · Sites in United States, Argentina, Canada and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8
First in 2014; this study’s year is marked. 2 started in 2015.
This study's enrollment of 231 is above the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.
Median enrollment 40 across the 8 interventional studies, 75 across the 3 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
1 of the studies in Neuromyelitis Optica by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06724809Phase 3Alexion Pharmaceuticals, Inc.Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
Inebilizumab is a genetically engineered humanized monoclonal antibody that binds to the B cell specific surface antigen cluster of differentiation (CD19) resulting in the depletion of B cells. Inebilizumab depletes antibody-secreting plasmablasts and some plasma cells, which are generally CD19 positive and CD20 negative.
The main objective of this study is to determine whether inebilizumab compare to placebo decreases the risk of an attack in participants with NMO/NMOSD.
This is a multicenter, multinational, randomized, double-masked, placebo controlled study with an open-label extension period to evaluate the efficacy and safety of intravenous (IV) inebilizumab in adult participants with NMO/NMOSD. After a screening period, eligible participants will enter a randomized-controlled period (RCP) of maximum 197 days where they will be randomized in a 3:1 ratio to receive either IV inebilizumab or placebo. NMO/NMOSD attacks will be evaluated by the investigator and confirmed against the attack criteria by an independent Adjudication Committee (AC). Participants for whom the attack was confirmed by the AC will be given the option to enroll into an open label period (OLP) with inebilizumab treatment. Participants who complete the RCP without experiencing an attack will be given the option to enroll into an OLP with inebilizumab treatment. The OLP will continue for a minimum of 1 year and a maximum of 3 years after the last participant enter the OLP. All participants who discontinue from the RCP or the OLP will continue in a Safety Follow-up for a total of 12 months from last dose to evaluate the long-term safety of the investigational product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmation of NMO/NMOSD status:
Exclusion Criteria:
Receipt of the following at any time prior to randomization:
Receipt of any of the following within 3 months prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aquaporin-4-antibody (AQP4-IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
Drug: Inebilizumab · Other: Placebo
AQP4-IgG sero positive and sero negative participants will IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
Drug: Inebilizumab · Other: Placebo
Participants will receive IV inebilizumab 300 mg.
Also known as: MEDI-551
Participants will receive IV placebo matched to inebilizumab.
Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP
The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria. These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide. Only attacks positively adjudicated by the AC were used for the primary analysis.
Time frame: Day 1 (Baseline) through Day 197
Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP
EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS). It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS). A negative change from baseline indicates improvement. A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.
Time frame: Day 1 (Baseline) through Day 197
Change From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP
Low-contrast visual acuity test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters. Binocular score is the number of letters read correctly on an eye chart using both eyes simultaneously. The total score ranges from 0-70. Higher score indicates better vision.
Time frame: Day 1 (Baseline) through Day 197
Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP
The number of new gadolinium-enhancing lesions and new or enlarging T2 lesions were measured by MRI of the brain, optic nerve, and spinal cord.
Time frame: From Screening (Day -28) to Day 197
Number of NMOSD-related In-patient Hospitalizations During RCP
Participants with relapsing NMOSD have recurrent attacks that can be severe and result in blindness, paralysis, and even death and consequently, such attacks frequently result in in-patient hospitalizations. In-patient hospitalization is defined as a stay in hospital that goes beyond midnight of the first day of admission.
Time frame: Day 1 (Baseline) through Day 197
Annualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab
Annualized attack rate is defined as total number of AC-determined attacks divided by total person years. Total person-years is calculated as the sum of the person-years for individual participant. Person-year for individual participant = (Date of last day before safety follow-up period - first inebilizumab dose date +1)/365.25. Annualized AC-determined NMOSD attack rate during any exposure to inebilizumab (in RCP and OLP) is reported.
Time frame: For participants randomized to inebilizumab: Day 1 of RCP through end of OLP (approximately 3.5 years); and for participants randomized to placebo: Day 1 of OLP through the end of OLP (approximately 3 years)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) During RCP
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the RCP.
Time frame: Day 1 (Baseline) through Day 197
Number of Participants With TEAEs and TESAEs During OLP
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP.
Time frame: Day 198 through end of OLP period (maximum of 3 years after the last participant entered, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)
Number of Participants With TEAEs and TESAEs During SFP (Open-label Population)
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. Participant who prematurely discontinued from the RCP or OLP entered in the SFP.
Time frame: Every 3 months for a total of 1 year after the last dose of study drug (approximately 3 years)
Number of Participants With TEAEs and TESAEs During SFP (Non-OLP Population)
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. The SFP started when a participant prematurely discontinues from the RCP or OLP.
Time frame: Every 3 months for a total of 1 year after the last dose of study drug (approximately 3 years)
Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During RCP
Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during RCP is reported.
Time frame: Day 1 (Baseline) through Day 197
Number of Participants With at Least a 2-Grade Shift From Baseline to Worst Toxicity Grade in Hematology and Chemistry During OLP
Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during OLP is reported.
Time frame: Day 198 through end of OLP (maximum of 3 years after the last participant enters, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)
Time to Maximum Serum Concentration (Tmax) of Inebilizumab (During RCP)
Time to maximum serum concentration of inebilizumab during RCP is reported.
Time frame: Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)
Maximum Observed Serum Concentration (Cmax) of Inebilizumab (During RCP)
Maximum observed serum concentration of inebilizumab during RCP is reported.
Time frame: Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)
Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab (During RCP)
Area under the serum concentration time curve of the dosing interval (AUC0-14d) of inebilizumab during RCP is reported.
Time frame: Dose 1 (Pre and post dose on Day 1 and Day 8); and Dose 2 (pre and post dose on Day 15; and Days 29, 57, 85, 113, 155, and 197)
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During RCP)
Number of participants with positive ADA titer to inebilizumab during RCP is reported.
Time frame: Pre and post dose on Day 1; and on Days 29, 85, and 197
Number of Participants With Positive Anti-Drug Antibodies (ADA) Titer to Inebilizumab (During OLP)
Number of participants with positive ADA titer to inebilizumab in OLP is reported.
Time frame: Pre and post dose on Day 1; and on Days 92, 183, 274, and then every 6 months (maximum of 3 years after the last participant enters, until regulatory approval or study discontinuation, whichever occurs first) (approximately 3 years)
| Milestone | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Started | 56 | 175 |
| Treated | 56 | 174 |
| Completed | 54 | 169 |
| Not completed | 2 | 6 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Participants randomized, but not treated | 0 | 1 |
| Withdrew: Other | 1 | 2 |
| Milestone | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Started | 51 | 165 |
| Completed | 43 | 131 |
| Not completed | 8 | 34 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 14 |
| Withdrew: Other | 6 | 15 |
The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria. These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide. Only attacks positively adjudicated by the AC were used for the primary analysis.
| Days | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP | NA (142.0 to NA) | NA (NA to NA) |
EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS). It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS). A negative change from baseline indicates improvement. A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.
| Percentage of Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the Last Visit of RCP | 33.9 | 14.9 |
Low-contrast visual acuity test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters. Binocular score is the number of letters read correctly on an eye chart using both eyes simultaneously. The total score ranges from 0-70. Higher score indicates better vision.
| Score on scale | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Change From Baseline in Low-Contrast Visual Acuity Binocular Score to the Last Visit of RCP | 1.442 ± 1.217 | 1.576 ± 0.935 |
The number of new gadolinium-enhancing lesions and new or enlarging T2 lesions were measured by MRI of the brain, optic nerve, and spinal cord.
| Number of lesions | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions During RCP | 2.3 ± 1.3 | 1.6 ± 1.0 |
Participants with relapsing NMOSD have recurrent attacks that can be severe and result in blindness, paralysis, and even death and consequently, such attacks frequently result in in-patient hospitalizations. In-patient hospitalization is defined as a stay in hospital that goes beyond midnight of the first day of admission.
| Number of In-patient Hospitalizations | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Number of NMOSD-related In-patient Hospitalizations During RCP | 1.4 ± 0.7 | 1.0 ± 0 |
Annualized attack rate is defined as total number of AC-determined attacks divided by total person years. Total person-years is calculated as the sum of the person-years for individual participant. Person-year for individual participant = (Date of last day before safety follow-up period - first inebilizumab dose date +1)/365.25. Annualized AC-determined NMOSD attack rate during any exposure to inebilizumab (in RCP and OLP) is reported.
| Annualized attack rate | Any Inebilizumab |
|---|---|
| Annualized AC-determined NMOSD Attack Rate During Any Exposure to Inebilizumab | 0.086 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the RCP.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| TEAEs | 41 | 127 |
| TESAEs | 6 | 9 |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| TEAEs | 45 | 144 |
| TESAEs | 19 | 22 |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. Participant who prematurely discontinued from the RCP or OLP entered in the SFP.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| TEAEs | 3 | 5 |
| TESAEs | 2 | 1 |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug during the OLP. The SFP started when a participant prematurely discontinues from the RCP or OLP.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| TEAEs | 2 | 3 |
| TESAEs | 1 | 1 |
Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during RCP is reported.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Hemoglobin (decreased) | 0 | 2 |
| Leukocytes (decreased) | 1 | 11 |
| Lymphocytes (decreased) | 5 | 35 |
| Lymphocytes (increased) | 4 | 1 |
| Neutrophils (decreased) | 0 | 10 |
| Alanine Aminotransferase (increased) | 1 | 4 |
| Aspartate Aminotransferase (increased) | 2 | 1 |
| Bilirubin (increased) | 2 | 1 |
| Cholesterol (increased) | 2 | 5 |
| Creatinine (increased) | 1 | 5 |
| Gamma glutamyl transferase (increased) | 1 | 6 |
| Glucose (decreased) | 1 | 1 |
| Glucose (increased) | 5 | 1 |
| Potassium (decreased) | 0 | 1 |
| Sodium (decreased) | 1 | 2 |
| Triglycerides (increased) | 2 | 7 |
Number of participants with at least a 2-grade shift from baseline to worst toxicity grade in hematology and chemistry during OLP is reported.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Hemoglobin (decreased) | 2 | 6 |
| Leukocytes (decreased) | 1 | 12 |
| Lymphocytes (decreased) | 9 | 21 |
| Lymphocytes (increased) | 1 | 4 |
| Neutrophils (decreased) | 1 | 16 |
| Alanine aminotransferase (increased) | 4 | 2 |
| Albumin (decreased) | 0 | 3 |
| Alkaline phosphatase (increased) | 1 | 1 |
| Aspartate aminotransferase (increased) | 2 | 3 |
| Cholesterol (increased) | 1 | 5 |
| Creatinine (increased) | 3 | 7 |
| Gamma glutamyl transferase (increased) | 1 | 10 |
| Glucose (decreased) | 0 | 3 |
| Glucose (increased) | 5 | 5 |
| Potassium (decreased) | 0 | 1 |
| Potassium (increased) | 1 | 2 |
| Sodium (decreased) | 2 | 1 |
| Triglycerides (increased) | 4 | 6 |
| Urate (increased) | 1 | 1 |
| Hemoglobin (increased) | 0 | 1 |
| Bilirubin | 2 | 0 |
Time to maximum serum concentration of inebilizumab during RCP is reported.
| Days | Inebilizumab/Inebilizumab |
|---|---|
| Dose 1 | 0.07 (0.07 to 7.00) |
| Dose 2 | 0.07 (0.07 to 14.00) |
Maximum observed serum concentration of inebilizumab during RCP is reported.
| μg/mL | Inebilizumab/Inebilizumab |
|---|---|
| Dose 1 | 97.7 ± 37.4 |
| Dose 2 | 108 ± 45.4 |
Area under the serum concentration time curve of the dosing interval (AUC0-14d) of inebilizumab during RCP is reported.
| μg*d/mL | Inebilizumab/Inebilizumab |
|---|---|
| Dose 1 | 667 ± 31.3 |
| Dose 2 | 967 ± 39.6 |
Number of participants with positive ADA titer to inebilizumab during RCP is reported.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| ADA positive at anytime including baseline (BL) | 8 | 17 |
| ADA positive at BL; not detected post-BL | 0 | 5 |
| ADA positive post-BL; positive at BL | 4 | 7 |
| ADA positive post-BL; not detected at BL | 4 | 5 |
Number of participants with positive ADA titer to inebilizumab in OLP is reported.
| Participants | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| ADA positive at any time including baseline (BL) | 9 | 22 |
| ADA positive at BL; not detected post-BL | 0 | 5 |
| ADA positive post-BL and positive at BL | 4 | 7 |
| ADA positive post-BL; not detected at BL | 5 | 10 |
Collected over From Day 1 through the end of study (approximately 5 years 10 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Inebilizumab | 1/56 (1.8%) | 24/56 (42.9%) | 48/56 (85.7%) |
| Inebilizumab/Inebilizumab | 2/174 (1.1%) | 28/174 (16.1%) | 138/174 (79.3%) |
| Event | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Urinary tract infectionInfections and infestations | 7/56 | 3/174 |
| PneumoniaInfections and infestations | 3/56 | 3/174 |
| HyponatraemiaMetabolism and nutrition disorders | 2/56 | 0/174 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 2/56 | 0/174 |
| Neuromyelitis optica spectrum disorderNervous system disorders | 2/56 | 3/174 |
| Acute kidney injuryRenal and urinary disorders | 2/56 | 0/174 |
| Hepatic failureHepatobiliary disorders | 1/56 | 0/174 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/56 | 0/174 |
| Back painMusculoskeletal and connective tissue disorders | 1/56 | 1/174 |
| Visual acuity reducedEye disorders | 1/56 | 0/174 |
| Event | Placebo/Inebilizumab | Inebilizumab/Inebilizumab |
|---|---|---|
| Urinary tract infectionInfections and infestations | 20/56 | 40/174 |
| HeadacheNervous system disorders | 13/56 | 31/174 |
| NasopharyngitisInfections and infestations | 11/56 | 38/174 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/56 | 28/174 |
| Upper respiratory tract infectionInfections and infestations | 10/56 | 28/174 |
| NauseaGastrointestinal disorders | 9/56 | 15/174 |
| Infusion related reactionInjury, poisoning and procedural complications | 9/56 | 22/174 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/56 | 11/174 |
| DiarrhoeaGastrointestinal disorders | 8/56 | 15/174 |
| Back painMusculoskeletal and connective tissue disorders | 8/56 | 24/174 |
The Intent-to-treat (ITT) population included all participants who were randomized, received any study drug, and grouped according to their randomized treatment.
| Age, Continuous(Years) | Placebo/Inebilizumab | Inebilizumab/Inebilizumab | Total |
|---|---|---|---|
| Mean | 42.6 ± 13.9 | 43.0 ± 11.6 | 42.9 ± 12.2 |
| Sex: Female, Male(Participants) | Placebo/Inebilizumab | Inebilizumab/Inebilizumab | Total |
|---|---|---|---|
| Female | 50 | 159 | 209 |
| Male | 6 | 15 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/Inebilizumab | Inebilizumab/Inebilizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 28 | 43 |
| Not Hispanic or Latino | 41 | 146 | 187 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo/Inebilizumab | Inebilizumab/Inebilizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 14 | 19 |
| Asian | 8 | 39 | 47 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 15 | 20 |
| White | 28 | 92 | 120 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 10 | 13 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2015 to primary completion in Oct 2018, 42 months.
Results were first posted in Dec 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab